Blog | BioInformant

Osaka’s Cell Grand Clinic Named Top Regenerative Medicine Solution Provider in APAC 2026 — Standardizes Patient-Specific ADSC Therapy Across 13 Government-Certified Programs

June 30, 2026 By BioInformant Team Leave a Comment

Japanese government-certified clinic applies ISCT-compliant flow-cytometry release criteria to patient-specific adipose-derived stem cell cultures, serving patients from approximately 20 countries

OSAKA, Japan — June 2026 — Cell Grand Clinic (CGC), a Japanese government-certified regenerative medicine clinic, has been named Top Regenerative Medicine Solution Provider in APAC 2026 by Healthcare Business Review APAC, recognition that places CGC among the region’s top 10 regenerative medicine providers. The clinic operates 13 Ministry of Health, Labour and Welfare (MHLW)-certified treatment plans — among the highest concentrations in Osaka — using autologous adipose-derived stem cell (ADSC) therapy for conditions spanning knee osteoarthritis, type 1 and type 2 diabetes, arteriosclerosis, age-related decline and whole-body anti-aging (frailty), and dermatologic and androgenetic applications, serving patients from approximately 20 countries. A 14th plan, autologous ADSC therapy for Alzheimer’s disease, is under MHLW review and is scheduled to launch in July 2026. [Read more…]

UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson’s Therapy

June 29, 2026 By BioInformant Team Leave a Comment

SHANGHAI, June 23, 2026 — UniXell Biotechnology Co., Ltd. (“UniXell”) has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for UX-DA003, its allogeneic induced pluripotent stem cell (iPSC)-derived therapy for Parkinson’s disease. Paired with the prior IND approval from China’s National Medical Products Administration (NMPA) on June 3, 2026, the candidate will undergo clinical development in both China and the United States concurrently, marking a landmark dual-country breakthrough for the company’s neurodegenerative disease pipeline. This milestone solidifies UniXell’s unique dual-pathway clinical strategy covering personalized autologous and scalable off-the-shelf allogeneic iPSC therapeutics.

[Read more…]

Anja Health Expands Partnership with Vitalant Cord Blood Stem Cell Laboratory to Advance Newborn Stem Cell Preservation

June 28, 2026 By BioInformant Team Leave a Comment

More Than 100 Years of Combined Experience Supporting Families and the Future of Regenerative Medicine

LOS ANGELES, CA, UNITED STATES, June 16, 2026 — Anja Health, a leading provider of newborn stem cell preservation services, announced the expansion of its partnership with the Vitalant Cord Blood Stem Cell Laboratory, one of the nation’s most respected stem cell processing and storage facilities, further strengthening Anja Health’s commitment to providing families with advanced cord blood, cord tissue, and placenta stem cell preservation services. [Read more…]

A Complete List of All Publicly Announced RMAT Designations (163)

June 28, 2026 By Cade Hildreth, Founder & President 8 Comments

To date, what number of U.S. FDA-approved RMATs have been issued and to whom have they been awarded?

The answer is that 163 RMAT (Regenerative Medicine Advanced Therapy) designations have been publicly announced by biotech and pharma companies. However, the FDA states it has received 388 requests and issued 193, which means that a handful are not yet public knowledge. Therefore, a few companies are operating in stealth mode with regard to their RMAT designations and approximately half of RMAT applications get approved (193 approvals / 388 applications = 49.7%).

[Read more…]

Cord for Life® Completes the First Clinical Trial Using Cord Blood Stem Cells for a Non-Transplant Medical Treatment of Lower Back Pain

June 27, 2026 By BioInformant Team Leave a Comment

ALTAMONTE SPRINGS, Fla. — In a historical moment for umbilical cord blood stem cell research, Cord for Life®, Inc. announces the completion of phase 1 of a clinical trial for lower back pain treatment. This marks the first time umbilical cord blood stem cells have been evaluated for a treatment not related to transplantation and regeneration of the recipient’s bone marrow to generate new blood cells. This early success could lead to numerous other trials for a wide range of treatments that could have a significant effect on the quality of life for tens of millions of patients worldwide. [Read more…]